- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Robin Shah: Biosimilars in Community Oncology
Robin Shah, chief commercial officer of OneOncology, addresses the role that biosimilars have in community oncology.
Transcript
We're really excited about some of the shifts in biosimilars. And this comes from a number of things. The first is the advancement of science in this space really is going to pave the future for opportunities for new drug classes to come into community oncology and oncology in general.
The second is, as we go into value-based arrangements, the important thing that comes with value-based is total cost of care. And with the introduction of biosimilars and a lot of the new relationships that OneOncology is going into, we're going to really be able to reduce the total cost of care with all these new agents being introduced to the marketplace.
And as you may have seen from our press release, we've gone into a large partnership on this front. And with the technology that we have, we can now really track and identify where we're complying with biosimilars, and where there are opportunities to shift some of our existing drug agents to new therapies that are coming out.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
